Search

Displaying results 5671 - 5680 of 9322 in total
  1. Drug

    ABT-510

    go.drugbank.com/drugs/DB05434
    Investigational

    It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.

  2. Drug

    Linsitinib

    go.drugbank.com/drugs/DB06075
    Investigational

    IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. … An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity.

  3. Drug

    STI-1499

    go.drugbank.com/drugs/DB16487
    Investigational

    STI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.

  4. Drug

    Tifuvirtide

    go.drugbank.com/drugs/DB05413
    Investigational

    Tifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.

  5. Drug

    Disoxaril

    go.drugbank.com/drugs/DB08726
    Experimental

    This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.

  6. Drug

    Edonerpic

    go.drugbank.com/drugs/DB05938
    Investigational

    Edonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.

  7. Drug

    Anatibant

    go.drugbank.com/drugs/DB05038
    Experimental

    It is developed for the for the treatment of traumatic brain injury (TBI).

  8. Drug

    CHF 4227

    go.drugbank.com/drugs/DB05882
    Experimental

    The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. … Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.

  9. Drug

    Mesmulogene ancovacivec

    go.drugbank.com/drugs/DB06584
    Investigational

    Vaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, … Expression of IL-2 augments the specific CTL response against MUC1 expressing cells. [L5191]

  10. Drug

    BHV-1310

    go.drugbank.com/drugs/DB22674
    Experimental

    BHV-1310 is a IgG<sub>1,2,4</sub> selective degrader being investigated for the treatment of Grave's disease.